Shared Immune and Stromal Programs Converge in Bronchiolitis Obliterans Syndrome

Bronchiolitis obliterans syndrome sits at the center of two transplant complications that look different on paper but appear to share a biological core in the lung. In one setting it follows lung transplantation as chronic lung allograft dysfunction CLAD-BOS; in the other, it emerges as the pulmonary manifestation of chronic graft-versus-host disease cGVHD-BOS after allogeneic hematopoietic stem cell transplant. Both are progressive and fatal obstructive lung diseases, and both remain poorly understood despite the clear signal that chronic alloreactivity drives injury in each condition.

Single-cell RNA sequencing of explanted human lungs now places immune and stromal cells on the same pathogenic map. The dataset included 4 patients with CLAD-BOS, 3 with cGVHD-BOS, and 3 deceased controls, allowing direct comparison at a resolution that bulk tissue studies cannot provide. The resulting cellular profile did not simply show inflammation; it showed coordinated remodeling across immune compartments, parenchymal support cells, and vascular-associated populations. In practical terms, BOS does not look like a lone airway disease. It looks like a multicellular failure state.

CD8+ Tissue-Resident Memory Cells Stand Out Across Both BOS Phenotypes

The most consistent immune signal was an expanded population of CD8+ tissue resident memory T cells TRM. These cells were distinct to BOS when compared with other chronic lung diseases, making them one of the clearest shared features between CLAD-BOS and cGVHD-BOS. TRM cells are positioned to remain in tissue rather than circulate freely, which makes them especially plausible drivers of persistent, localized immune injury in the small airways. Their persistence fits the clinical pattern of BOS, where ongoing inflammatory pressure slowly narrows the bronchiolar lumen and progressively limits airflow.

A one-sentence reality check follows directly from the biology: these lungs were not simply inflamed, they were immunologically occupied.

The relevance of TRM expansion is hard to miss in a disease defined by chronicity. Resident T cells can maintain antigen-experienced responses without requiring continual recruitment from the bloodstream, which helps explain how alloreactive injury can keep smoldering after the original transplant trigger has passed. In both transplant contexts, the same cellular strategy may be keeping the airway in a constant state of low-grade attack.

Macrophage Recruitment and Stromal Dysfunction Share the Same Stage

The immune signal did not stop with T cells. BOS samples expressed genes and pathways linked to macrophage chemotaxis and proliferation, and those programs appeared not only in immune cells but also in nonimmune cell populations. That pattern matters because it suggests the tissue microenvironment is actively instructing macrophage accumulation rather than merely responding to it. The study’s gene-expression and pathway analyses pointed to a coordinated network involving damage-associated molecular patterns, colony-stimulating factor signaling, chemokines, and leukocyte adhesion machinery.

Alveolar macrophages in CLAD-BOS showed enrichment for gene ontology terms related to migration, adhesion, and cytokine response. CXCL8 expression appeared in CD45-negative cell subsets, and putative CSF1 signaling linked endothelial and stromal populations to macrophage subsets. Those interactions were not isolated curiosities. They suggest a feed-forward loop in which injured structural cells help recruit and sustain macrophages, and the macrophages in turn amplify inflammatory and remodeling cues. In a small-airway disease, that kind of loop can accelerate narrowing long before spirometric collapse becomes irreversible.

Dysfunctional stromal cells added another layer. BOS stromal populations were characterized by both pro-fibrotic and anti-fibrotic gene programs, a combination that signals disordered repair rather than simple scar formation. Fibrosis in this setting is unlikely to be a linear process. Instead, the tissue appears to oscillate between injury responses and incomplete repair, leaving behind a structurally unstable airway wall that is vulnerable to collapse, obstruction, and progressive loss of function.

Why CLAD-BOS and cGVHD-BOS May Be More Similar Than Different

The overlap between the lung-transplant and hematopoietic-stem-cell-transplant forms of BOS is one of the most clinically relevant features of the analysis. Chronic alloreactivity is common to both diseases, and the shared cellular architecture seen here supports a common pathogenic framework rather than two unrelated syndromes with similar spirometric endings. The lung, in both settings, appears to mount a combined immune and stromal response that is capable of sustaining itself over time.

That shared biology opens a therapeutic door, even if the study itself does not test treatment. A therapy that can interrupt resident CD8+ T-cell persistence, reduce macrophage recruitment, or reprogram dysfunctional stromal signaling could be relevant across both CLAD-BOS and cGVHD-BOS. The challenge is precision: suppressing the wrong arm of repair could blunt host defense or worsen tissue instability. The cellular data nonetheless make a strong case that BOS should be approached as a network disease, not a single-pathway problem.

Limits of the Dataset and the Path to Therapeutic Targeting

The cohort was small, and explanted lungs represent end-stage disease rather than early, interceptable pathology. That limitation is built into the tissue source itself. The findings are therefore strongest as mechanistic evidence, not as a direct guide to when the disease begins or which biomarker should be used first in clinic. The control group also consisted of deceased lungs, which is useful for comparison but cannot substitute for a perfectly matched living donor or longitudinal sampling design.

Even so, the single-cell data do more than describe terminal injury. They identify a convergent set of immune and stromal pathways that likely shape the trajectory of BOS in both transplant settings. The expanded CD8+ TRM compartment, the macrophage migration program, and the dysfunctional stromal signature together form a coherent explanation for why bronchiolar obliteration can become self-perpetuating. Future work will need to determine whether these populations are drivers, markers, or both, and whether they can be altered before airway loss becomes fixed.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Journal of Clinical Investigation.